BeStock  
Stocks › Medical Devices › IART

Integra Lifesciences IART

US equityMarket cap rank #3137Medical DevicesBrain-Computer Interface
$13.25 −$0.30 (-2.21%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $12.99 -1.96%
Open$13.38
Prev close$13.55
Day range$13.16 – $13.79
Volume828.6K
Market cap$1.03B
P/E (TTM)77.9
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership113.6%+7.03 pts vs. prior quarter
Institutions holding275+12 vs. prior quarter
Insider trades (recent)28 buys / 19 sellsNet buying
Short interest10.15% of floatDays to cover 6.4 · as of 30 Oct 2026
Short-sale volume share28.7%5-day average of daily volume

Short-sale volume as % of daily volume

15%24%33%42%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$2.56M (7 inflow days, 13 outflow days).

Net flow by order size, last 20 sessions

−$1.5MSuper−$1.1MBig−$808.6KMid−$1.9MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 44.8% of shares outstanding.

Largest holders

  • BlackRock13.91%
  • Tru St Partnership LP10.95%
  • Rubric Capital Management LP9.97%
  • Vanguard Portfolio Management, LLC5.06%
  • Invesco Ltd.4.91%
  • Morgan Stanley4.81%
  • Paradigm Capital Management, Inc.4.42%
  • Vanguard Capital Management, LLC4.36%

By investor type

  • Mutual Fund76.00%
  • Hedge Fund16.05%
  • Private Company11.51%
  • Public Company8.21%
  • Individual/Insider3.69%
  • Government Pension Fund1.36%
  • Insurance Company0.32%
  • Government0.03%

Reported short interest has risen from 8.67% to 10.15% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Dimensional Fund Advisors Mutual Fund 2026/Q3 +548,778 3.6%
LSV Asset Management Mutual Fund 2026/Q3 +500,349 0.9%
Invesco Ltd. Mutual Fund 2026/Q3 +391,757 4.9%
JPMorgan Chase & Co. Public Company 2026/Q3 +391,117 0.6%
Vanguard Portfolio Management, LLC Mutual Fund 2026/Q3 +196,675 5.1%
Access Investment Management, LLC Mutual Fund 2026/Q3 +159,980 0.7%
Morgan Stanley Public Company 2026/Q3 +147,655 4.8%
BlackRock Mutual Fund 2026/Q3 +141,825 13.9%
Russell Investment Management, LLC Mutual Fund 2026/Q3 +134,320 0.2%
PanAgora Asset Management, Inc. Mutual Fund 2026/Q3 +120,349 0.2%
Nuveen Asset Management LLC Insurance Company 2026/Q3 +160,130 0.2%
Millennium Management LLC Hedge Fund 2026/Q3 +816,894 1.9%
Integral Health Asset Management, LLC Hedge Fund 2026/Q3 +550,000 0.7%
BlackRock Mutual Fund 2026/Q3 +364,934 13.7%
Invesco Ltd. Mutual Fund 2026/Q3 +354,779 4.4%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
30 Sep 2026 Andrea Caruso CVP & CHRO Initial Statement of Beneficial +0 – 24,211
16 Sep 2026 Lesha Shinn Initial Statement of Beneficial +0 – 26,838
31 Aug 2026 Chantal Veillon-Berteloot Former Chief Human Resources Officer Sale to Issuer -1,455 $16.62 20,772
2 Jul 2026 Lea Knight Chief Financial Officer Sale to Issuer -5,226 $18.05 45,263
30 Jun 2026 Robert Davis Executive Vice President of Tissue Reconstruction and Distributed Technologies Other Derivative Acquisition +11,180 – 54,530
30 Jun 2026 Jeffrey Mosebrook Senior VP of Finance & Principal Accounting Officer Sale to Issuer -937 $17.89 34,516
30 Jun 2026 Harvinder Singh Executive VP & President of International Business Other Derivative Acquisition +5,590 – 68,883
31 May 2026 Stuart Essig Chief Executive Officer Other Derivative Acquisition +365,297 – 365,297
31 May 2026 Stuart Essig Chief Executive Officer Other Derivative Acquisition +705,468 $15.67 705,468
31 May 2026 Michael McBreen Executive Vice President Other Derivative Acquisition +31,909 – 124,017
31 May 2026 Michael McBreen Executive Vice President Other Derivative Acquisition +60,372 $15.67 60,372
8 May 2026 Keith N. Bradley Independent Director Sale to Issuer -882 $13.92 88,254
6 May 2026 Christian Schade Independent Director Other Derivative Acquisition +17,700 – 17,700
6 May 2026 Barbara Hill Independent Director Other Acquisition +24,338 – 187,541
6 May 2026 Keith N. Bradley Independent Director Other Derivative Acquisition +17,700 – 17,700
6 May 2026 Jeffrey Graves Independent Director Other Derivative Acquisition +17,700 – 17,700
6 May 2026 Shaundra Clay Independent Director Other Derivative Acquisition +17,700 – 17,700
6 May 2026 Renee Lo Independent Director Other Derivative Acquisition +17,700 – 17,700
10 Mar 2026 Robert Davis Executive Vice President of Tissue Reconstruction and Distributed Technologies Other Derivative Acquisition +43,350 – 43,350
10 Mar 2026 Mojdeh Poul Former Chief Executive Officer Other Derivative Acquisition +343,393 – 445,691

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 7,895,702 10.1% 6.4
15 Oct 2026 7,316,999 9.4% 5.5
30 Sep 2026 7,266,960 9.3% 7.5
15 Sep 2026 6,806,086 8.8% 8.3
31 Aug 2026 6,858,036 8.8% 12.3
14 Aug 2026 6,742,359 8.7% 10.0

Discussion

No comments yet — be the first to weigh in on IART.

Sign in to join the discussion.

Scroll to Top